0001437749-19-001211.txt : 20190123 0001437749-19-001211.hdr.sgml : 20190123 20190123163015 ACCESSION NUMBER: 0001437749-19-001211 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190116 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20190123 DATE AS OF CHANGE: 20190123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aeon Global Health Corp. CENTRAL INDEX KEY: 0000885074 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 141673067 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-20190 FILM NUMBER: 19537729 BUSINESS ADDRESS: STREET 1: 2225 CENTENNIAL DRIVE CITY: GAINESVILLE STATE: 2Q ZIP: 30504 BUSINESS PHONE: 888-661-0225 MAIL ADDRESS: STREET 1: 2225 CENTENNIAL DRIVE CITY: GAINESVILLE STATE: 2Q ZIP: 30504 FORMER COMPANY: FORMER CONFORMED NAME: AUTHENTIDATE HOLDING CORP DATE OF NAME CHANGE: 20010327 FORMER COMPANY: FORMER CONFORMED NAME: BITWISE DESIGNS INC DATE OF NAME CHANGE: 19930328 8-K 1 aghc20190118b_8k.htm FORM 8-K aghc20190118b_8k.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 16, 2019

 

AEON GLOBAL HEALTH CORP.
(Exact name of registrant as specified in its charter)

 

COMMISSION FILE NUMBER:  0-20190

 

DELAWARE

14-1673067

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

 

2225 Centennial Drive

Gainesville, GA 30504

(Address and zip code of principal executive offices)

 

1-(888) 661-0225
(Registrant's telephone number, including area code

 

CHECK THE APPROPRIATE BOX BELOW IF THE FORM 8-K FILING IS INTENDED TO SIMULTANEOUSLY SATISFY THE FILING OBLIGATION OF THE REGISTRANT UNDER ANY OF THE FOLLOWING PROVISIONS:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

1
 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

 

On December 6, 2018, Aeon Global Health Corp. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). As reported by the Company on a Current Report on Form 8-K filed on December 11, 2018, the Annual Meeting was adjourned with respect to Proposal 4, the approval of an amendment to the Company’s Amended Certificate of Incorporation to continue to restrict certain transfers of Common Stock to preserve the tax treatment of the Company’s net operating losses and other tax benefits.

 

On January 16, 2019, the Company reconvened the Annual Meeting with respect to Proposal 4 at the Company’s corporate headquarters, located at 2225 Centennial Drive, Gainesville, Georgia 30504. Only stockholders of record as of the close of business on October 19, 2018 were entitled to vote. As of the record date, 7,383,706 shares of common stock of the Company were outstanding and entitled to vote at the Annual Meeting.  On the Annual Meeting adjournment date, 6,681,548 shares of common stock of the Company were represented, in person or by proxy, constituting a quorum. The proposal is described in further detail in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on October 26, 2018, as supplemented. The proposal did not receive a sufficient number of votes for passage. Set forth below are the shareholder votes on Proposal 4:

  

For

  

Against

  

Abstain

  

Broker Non-Votes

3,261,295

  

490,600

  

9,421

  

2,920,232

 

2
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

AEON GLOBAL HEALTH CORP.
   

 

 

 

By: /s/  Hanif A. Roshan

 

Name: Hanif A. Roshan

 

Title:   Chief Executive Officer 

 Date:   January 23, 2019

  

 

3